Welcome to our dedicated page for Eikon Therapeutics SEC filings (Ticker: EIKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eikon's filings are most useful for verifying its public-company status, material corporate events, and clinical-stage financial disclosures. The company’s Form 8-K record documents Nasdaq-registered common stock under EIKN, the closing of its initial public offering, amendments to its certificate of incorporation and bylaws, and results of operations and financial condition tied to clinical and corporate updates.
The most decision-useful disclosures for Eikon are the 8-K exhibits and governance filings that connect financing, corporate structure, and pipeline activity. These filings help confirm how Eikon describes its oncology programs, how it reports research and development and general and administrative expenses, and how its public-company documents frame the business after the IPO.
Eikon Therapeutics, Inc. reported that, in connection with the closing of its initial public offering on February 6, 2026, it put in place a new legal and governance framework. Immediately prior to the IPO closing, the company’s board and stockholders approved an amended and restated certificate of incorporation and amended and restated bylaws.
The restated certificate of incorporation was filed with the Delaware Secretary of State, and the updated bylaws became effective on February 6, 2026. These documents define the company’s capital structure and core governance rules as a newly public company whose common stock trades on the Nasdaq Stock Market under the symbol EIKN.
Eikon Therapeutics, Inc. is conducting an initial public offering of 21,177,600 shares of common stock at $18.00 per share, for a stated gross offering amount of $381,196,800 and estimated net proceeds to the company, before expenses, of $354,513,024. Underwriters have a 30‑day option to buy up to 3,176,640 additional shares at the same price, less underwriting discounts and commissions. The stock is approved for listing on the Nasdaq Global Select Market under the symbol “EIKN.”
Eikon is a late‑stage clinical biopharmaceutical company focused on oncology, with multiple product candidates in Phase 1/2 and Phase 2/3 trials, including toll‑like receptor and selective PARP1 inhibitors, a WRN helicase inhibitor, and androgen receptor programs. The company estimates cash, cash equivalents and short‑term investments of approximately $336.0 million as of December 31, 2025, but has reported recurring net losses of about $244.6 million for the nine months ended September 30, 2025 and an accumulated deficit of $840.9 million. Its own analysis notes substantial doubt about its ability to continue as a going concern without raising additional capital.